Sign in
4

Changes in Ownership

TEVA PHARMACEUTICAL INDUSTRIES LTD Filed Acc 0000950170-25-034607

Exec. VP, European Commercial sold 140,372 shares at an average $15.80 ($2,217,407)

  • Exec. VP, European Commercial acquired 237,142 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Daniell Richard · Exec. VP, European Commercial

Table I: Non-derivative

9 lines
Date Transaction Shares Price Value Owned after D/I
2025-03-04 Exercise or conversion : show line 1 in the form 10b5-1 +33,512 33,512 D
2025-03-04 Sale : show line 2 in the form 10b5-1 −21,870 $15.73 $344,116 11,641 D
2025-03-05 Sale : show line 3 in the form 10b5-1 −11,641 $15.91 $185,246 0 D
2025-03-04 Exercise or conversion : show line 4 in the form 10b5-1 +20,461 20,461 D
2025-03-04 Sale : show line 5 in the form 10b5-1 −13,353 $15.73 $210,104 7,108 D
2025-03-05 Sale : show line 6 in the form 10b5-1 −7,108 $15.91 $113,111 0 D
2025-03-04 Exercise or conversion : show line 7 in the form 10b5-1 +183,169 183,169 D
2025-03-04 Sale : show line 8 in the form 10b5-1 −56,385 $15.73 $887,195 126,784 D
2025-03-05 Sale : show line 9 in the form 10b5-1 −30,015 $15.91 $477,635 96,769 D
Open-market sales · 140,372 sh · avg $15.80 · $2,217,407

Table II: Derivative

3 lines
Date Transaction Shares Owned after D/I
2025-03-04 Exercise or conversion : show line 10 in the form 10b5-1 Restricted Share Units −33,512 33,512 D
2025-03-04 Exercise or conversion : show line 11 in the form 10b5-1 Restricted Share Units −20,461 61,384 D
2025-03-04 Exercise or conversion : show line 12 in the form 10b5-1 Restricted Share Units −183,169 0 D
Loading xslF345X05/ownership.xml…